Monte Rosa Therapeutics, Inc. (GLUE)
NMS · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 23.2M | 12.8M | 2.8M | 4.2M |
| Operating Income | -15.6M | -33.0M | -49.7M | -50.0M |
| Net Income | -12.3M | -27.1M | -46.1M | -44.5M |
| Diluted EPS | $-0.20 | $-0.44 | $-0.70 | $-0.45 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 75.6M | 123.7M |
| Operating Income | -112.4M | -143.3M | -81.1M | -54.2M |
| Net Income | -108.5M | -135.4M | -72.7M | -38.6M |
| Diluted EPS | $-2.30 | $-2.63 | $-1.18 | $nan |